BioNTech (BNTX) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic achievements and financial position

• Delivered five billion vaccine doses globally, maintaining COVID market leadership with a fifth variant-adapted vaccine and over 50% global market share in key regions.

• Advanced 25 late-stage clinical programs, with 15 phase III readouts expected in 2026–2027, and maintained a cash position exceeding $17 billion (€17.2 billion as of Dec 2025).

• Executed strategic deals, including partnerships with BMS and acquisitions of Biotheus and CureVac, strengthening oncology and mRNA capabilities.

• High-margin COVID-19 vaccine business funds oncology innovation, with modest Comirnaty revenue decline expected in 2026 and increased 2025 revenue guidance to €2.6–2.8 billion.

• Integrated AI and advanced manufacturing to accelerate clinical translation and maintained disciplined resource allocation focused on late-stage value creation.

Oncology pipeline and development strategy

• Over 25 ongoing phase 2 & 3 oncology trials, with late-stage readouts expected in 2026–2027 and a focus on combination therapy momentum.

• Pursuing a synergy-driven strategy across immunomodulators, ADCs, and mRNA cancer immunotherapies, with diversification to mitigate execution risk.

• Key assets include Prometimic (PD-L1/VEGF bispecific), Gotistobart (CTLA-4 Treg depleting), and BNT324/DB-1311 (B7-H3 ADC), with multiple registrational trials ongoing or planned.

• Building a multi-product oncology company by 2030, targeting 17+ late-stage/pivotal trial readouts.

• Combination strategies are central, with ongoing studies pairing ADCs, mRNA vaccines, and immunotherapies to enhance efficacy and durability.

Clinical milestones and future outlook

• 2026 will feature five late-stage readouts, including HER2 ADC, Gotistobart, HPV vaccine, Prometimic in TNBC, and a personalized colorectal cancer vaccine.

• Over 15 data readouts anticipated in 2026, supporting rapid decision-making and value creation, with sustained clinical output expected through 2029.

• No anticipated oncology product revenues in 2026; BMS collaboration revenues expected to remain stable.

• Building launch readiness and market access capabilities for anticipated first oncology product launches.

• Financial priorities include continued organic pipeline development, potential acquisitions, and future consideration of broader cash utilization as revenue visibility improves.